NCT01077531 - Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2010

Primary Completion Date

March 19, 2013

Study Completion Date

March 19, 2013

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

Otelixizumab

Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).

DRUG

Matching placebo

Matching placebo for intravenous infusion

Trial Locations (7)

15706

GSK Investigational Site, Santiago de Compostela

39008

GSK Investigational Site, Santander

115522

GSK Investigational Site, Moscow

119121

GSK Investigational Site, Moscow

150003

GSK Investigational Site, Yaroslavl

CB2 0QQ

GSK Investigational Site, Cambridge

NE1 4LP

GSK Investigational Site, Newcastle